• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Apellis Pharmaceuticals Inc (NQ: APLS )

    26.88 -1.12 (-4.00%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,299,201
    Open 27.93
    Bid (Size) 26.66 (8)
    Ask (Size) 27.00 (5)
    Prev. Close 28.00
    Today's Range 26.53 - 28.00
    52wk Range 26.28 - 73.80
    Shares Outstanding 116,457,008
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
    Via Benzinga
    Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
    William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
    Via Benzinga

    Performance

    YTD
    -56.13%
    -56.13%
    1 Month
    -17.32%
    -17.32%
    3 Month
    -27.45%
    -27.45%
    6 Month
    -43.58%
    -43.58%
    1 Year
    -40.79%
    -40.79%

    More News

    Read More
    Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
    Via Benzinga
    Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
    Via Benzinga
    Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    What's Going With Apellis Pharmaceuticals Stock Friday?
    Via Benzinga
    Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
    Via Investor's Business Daily
    Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
    Via Benzinga
    What Analysts Are Saying About Apellis Pharmaceuticals Stock
    Via Benzinga
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
    Via InvestorPlace
    Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
    Via Benzinga
    Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.